Johnson & Johnson Boosts U.S. Investments to $55B
Expansion Amid Tariff Threats Johnson & Johnson (JNJ.N) announced plans to increase its U.S. investments by 25% to more than $55 billion over the next four years. The move comes as the
Moderna Reports Larger-Than-Expected Quarterly Loss
Biotech firm Moderna (MRNA.O) reported a bigger-than-expected quarterly loss, primarily due to charges related to scaling down manufacturing as demand for its COVID-19 vaccine weakens. The company posted a quarterly loss of
Pfizer Raises Revenue Outlook Amid Pressure to Prove Post-COVID Value
Pfizer has raised its revenue and earnings outlook for the year, now expecting between $61 billion and $64 billion in revenue and adjusted earnings per share of $2.75 to $2.95. This optimistic
Pfizer Stock Rises on Upbeat 2025 Outlook and Guidance
Pfizer’s (PFE) stock climbed in pre-market trading on Tuesday after the pharmaceutical giant shared a positive full-year outlook for 2025. The company’s projections align closely with Wall Street estimates, signaling stability and
